Coronary Artery Disease in Patients Older than 35 and Eligible for Cardiovascular Secondary Prevention: An Italian Retrospective Observational Analysis of Healthcare Administrative Databases

Study type

• Study topic:
  Disease /health condition
• Study type:
  Non-interventional study
• Scope of the study:
  Drug utilisation

  Healthcare resource utilisation
• Data collection methods:
  Secondary use of data

Non-interventional study

• Non-interventional study design:
  Cohort

Study drug and medical condition

• Anatomical Therapeutic Chemical (ATC) code:
  (B01AC) Platelet aggregation inhibitors excl. heparin

  Platelet aggregation inhibitors excl. heparin

  (C07A) BETA BLOCKING AGENTS

  BETA BLOCKING AGENTS

  (C09A) ACE INHIBITORS, PLAIN

  ACE INHIBITORS, PLAIN

  (C09B) ACE INHIBITORS, COMBINATIONS

  ACE INHIBITORS, COMBINATIONS

  (C09C) ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN

  ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN

  (C09D) ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS

  ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS

  (C10) LIPID MODIFYING AGENTS

  LIPID MODIFYING AGENTS
• Medical condition to be studied:
  Coronary artery disease

Population studied

• Short description of the study population:
  Among all patients older than 35 in the ReS database in 2018, and with at least a healthcare resource consumption in the charge of the SSN since 2015, subjects who were admitted to hospital at least once in 2018 (accrual) and whose hospital discharge contained a primary/secondary diagnosis of CAD and/or a procedure on coronary arteries, or patients with a CAD-specific cost sharing exemption code, were selected for the analysis.

Study design details

• Study design:
  Retrospective longitudinal cohort study
• Main study objective:
  This study describes patients with coronary artery disease (CAD) who are eligible for secondary prevention and assesses their healthcare consumption and costs from the perspective of the Italian National Health Service (SSN)
• Setting:
  In-hospital and outpatient setting in public and affiliated with the SSN facilities
• Summary results:
  From >3 million inhabitants aged >= 35, 46,063 (1.3%) were identified (72.1% males, mean age 70 (12) years; approximately 50% with >=3 comorbidities). During a one-year follow-up, 96.4% were treated with >=1 drug for secondary prevention (mainly antiplatelets and lipid lowering agents), 69.4% with >=1 concomitant cardiovascular drug, and 95.8% with >=1 concomitant non-cardiovascular therapy. Within one year, 30.6% of patients were ospitalized at least once, mostly due to non-cardiovascular events. Calculated by mean, the SSN paid EUR 6078 per patient.